Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03032783
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : December 9, 2020
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

Brief Summary:
This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies. Giving total-body irradiation and chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.

Condition or disease Intervention/treatment Phase
Hematopoietic and Lymphoid Cell Neoplasm Radiation: Total-Body Irradiation Procedure: Donor Lymphocyte Infusion Drug: Cyclophosphamide Drug: Tacrolimus Drug: Mycophenolate Mofetil Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Phase 2

Detailed Description:

Primary Objective:

1. To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step HSCT utilizing strategies to decrease relapse.

Secondary Objective:

  1. To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on this protocol.
  2. To assess regimen related toxicity and GVHD incidence at 2 years post-HSCT and severity in patients undergoing treatment on this protocol.
  3. To assess the consistency and pace of engraftment.
  4. To assess the pace of T cell and B cell immune recovery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Actual Study Start Date : January 31, 2017
Estimated Primary Completion Date : July 24, 2021
Estimated Study Completion Date : July 24, 2021

Arm Intervention/treatment
Experimental: Treatment (TBI, DLI, chemotherapy, HSCT)
Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
Radiation: Total-Body Irradiation
Undergo Total Body Irradiation
Other Name: Total Body Irradiation

Procedure: Donor Lymphocyte Infusion
Undergo Donor Lymphocyte Infusion
Other Names:
  • DLI
  • Donor Leukocyte Infusion

Drug: Cyclophosphamide
Given IV
Other Names:
  • (-)-Cyclophosphamide
  • 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate
  • 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
  • 6055-19-2
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Clafen
  • CP monohydrate
  • CTX
  • Cycloblastin
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • WR- 138719

Drug: Tacrolimus
Given IV
Other Names:
  • Fujimycin
  • 717865
  • 109581-93-3
  • Hecoria
  • Prograf
  • Protopic

Drug: Mycophenolate Mofetil
Given IV
Other Names:
  • 115007-34-6
  • 128794-94-5
  • 724229
  • Cellcept

Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Undergo Hematopoietic Stem Cell Transplantation
Other Names:
  • HSCT
  • HSC




Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: At two years ]
    Will be tested using an exact one-sided binomial test with alpha 0.05. The trial will be considered successful if the null hypothesis of 45% 2-year OS is rejected. In addition, the exact binomial 95% confidence interval for 2-year OS will be computed.


Secondary Outcome Measures :
  1. Incidence of graft failure [ Time Frame: Up to 2 years ]
    Should be less than 10%

  2. Incidence of non-relapse mortality [ Time Frame: Up to 2 years ]
    Should be less than 20% at 100 days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

This treatment is for patients with high risk hematologic malignancies. High risk is defined as:

  • Any patient with a hematologic malignancy in which allogeneic HSCT is pursued with the expectation of cure. Patients may have post-treatment residual disease, but the disease should be stable or minimally progressive and must be responsive to chemotherapy.
  • Any patient with an untreated hematologic malignancy in which allogeneic HSCT is thought to be the sole or the best option for cure and in Patients without morphologic evidence of disease but with high risk features which would predict for relapsed despite remission at HSCT such as adverse cytogenetics, 3rd or greater CR, or failure to recover peripheral blood counts to normal ranges. While these patients do not have detectable disease by current methods, like all patients they have non-detectable disease which in their case is highly aggressive.
  • Patients with uncommon diagnoses in which allogeneic HSCT is thought to be beneficial but are no comparable to the majority of patients on this protocol will not be counted in the statistical aims of the study and will be reported descriptively. The PI and at least one Co-I must document this exception in the study binder and the rationale for descriptive report. An example of a patient who may meet this criteria is someone with a malignancy that is an overlap of two different diagnoses or one whose malignancy is difficult to categorize. While this circumstance is expected to be rare, it will prevent patients with rare diagnoses to be treated off study and it will help maintain homogeneity of the study population.
  • Patients must have one related donor who is HLA mismatched in the GVHD direction at two or more HLA loci (except as described below)
  • Patients must have adequate organ function:
  • Left Ventricular Ejection Fraction (LVEF) of ≥50%
  • DLCO (adjusted for hemoglobin) ≥50% of predicted and FEV-1 ≥50%
  • Adequate liver function as defined by a serum bilirubin ≤1.8, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN)
  • Creatinine clearance of ≥ 60ml/min
  • Karnofsky Performance Status (KPS) of ≥80% on the modified KPS tool (see Appendix)
  • Patients must be willing to use contraception if they have childbearing potential
  • Able to give informed consent
  • Age ≥ 18 years of age

Exclusion Criteria:

  • Modified KPS of <80%
  • > 5 Comorbidity Points on the Hematopoietic Cell Transplant Co-Morbidity Index (HCT CI) (See Appendix) (Patients with greater than 5 points will be allowed for trial with approval of the PI and at least 1 Co-I not on the primary care team of the patient.) this is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities.
  • Human Immunodeficiency Virus (HIV) positive
  • Active involvement of the central nervous system with malignancy
  • Psychiatric disorder that would preclude patients from signing an informed consent
  • Pregnancy, or unwillingness to use contraception if they have childbearing potential
  • Patients with life expectancy of ≤ 6 months for reasons other than their underlying hematologic/oncologic disorder
  • Alemtuzumab treatment within 8 weeks of HSCT admission
  • ATG within 8 weeks of HSCT administration
  • Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03032783


Contacts
Layout table for location contacts
Contact: Dolores Grosso, DNP 215-955-8874 dolores.grosso@jefferson.edu
Contact: Neal Flomenberg, MD neal.flomenberg@jefferson.edu

Locations
Layout table for location information
United States, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Dolores Grosso, DNP    215-955-8874      
Sponsors and Collaborators
Sidney Kimmel Cancer Center at Thomas Jefferson University
Investigators
Layout table for investigator information
Principal Investigator: Dolores Grosso, DNP Sidney Kimmel Cancer Center at Thomas Jefferson University
Additional Information:
Layout table for additonal information
Responsible Party: Sidney Kimmel Cancer Center at Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT03032783    
Other Study ID Numbers: 16D.606
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: December 9, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Neoplasms
Neoplasms by Site
Hematologic Diseases
Mycophenolic Acid
Cyclophosphamide
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Calcineurin Inhibitors
Enzyme Inhibitors
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents